Synergistic effects of FGFR1 and PLK1 inhibitors target a metabolic liability in KRAS‐mutant cancer

KRAS oncoprotein is commonly mutated in human cancer, but effective therapies specifically targeting KRAS‐driven tumors remain elusive. Here, we show that combined treatment with fibroblast growth factor receptor 1 (FGFR1) and polo‐like kinase 1 (PLK1) inhibitors evoke synergistic cytotoxicity in KR...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Zhang, Liang, Shun‐Qing, Saliakoura, Maria, Yang, Haitang, Vassella, Eric, Konstantinidou, Georgia, Tschan, Mario, Hegedüs, Balazs, Zhao, Liang, Gao, Yanyun, Xu, Duo, Deng, Haibin, Marti, Thomas M, Kocher, Gregor J, Wang, Wenxiang, Schmid, Ralph A, Peng, Ren‐Wang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8422071/
https://www.ncbi.nlm.nih.gov/pubmed/34369083
http://dx.doi.org/10.15252/emmm.202013193

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8422071/
https://www.ncbi.nlm.nih.gov/pubmed/34369083
http://dx.doi.org/10.15252/emmm.202013193

Ejemplares similares